Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Follow-Up Questions
Who is the CEO of Prostatype Genomics AB?
Fredrik Persson is the Chief Executive Officer of Prostatype Genomics AB, joining the firm since 2017.
What is the price performance of PGABF stock?
The current price of PGABF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Prostatype Genomics AB?
Prostatype Genomics AB belongs to Biotechnology industry and the sector is Health Care
